Prospective Pilot Study of Second Primary Tumor Prevention With Erlotinib and Celecoxib in Early‐Stage Squamous Cell Carcinoma of the Head and Neck: Long‐Term Follow‐Up
Head & Neck2025Vol. 47(9), pp. 2594–2602
Citations Over TimeTop 22% of 2025 papers
Pauline Kim, Nabil F. Saba, Ashley A. McCook‐Veal, Yuan Liu, Adam M. Klein, Jonathan J. Beitler, Amy Chen, Fadlo R. Khuri, Dong M. Shin
Abstract
Clinicaltrials.gov identifier: NCT00400374.
Related Papers
- → Concentrations of Erlotinib in Tumor Tissue and Plasma in Non–Small-Cell Lung Cancer Patients After Neoadjuvant Therapy(2014)23 cited
- → Multistep continuous flow synthesis of Erlotinib(2023)11 cited
- → Erlotinib sensitivity of MAPK1p.D321N mutation in head and neck squamous cell carcinoma(2020)9 cited
- → Gene expression profiling on pre‐ and post‐erlotinib tumors from patients with head and neck squamous cell carcinoma(2012)8 cited
- Effects of erlotinib combined with celecoxib on growth and angiogenesis of human lung cancer xenograft model(2013)